NeuroSense Therapeutics Ltd. (NRSN) meets investors at the 5th Annual ROTH Healthcare Opportunities Conference, hosted by ROTH Capital Partners at The Metropolitan Club in New York City on Tuesday, September 29, 2026, where B2i Digital is the Marketing Partner. The 5th Annual ROTH Healthcare Opportunities Conference is a B2i Digital Featured Conference. See event details and profiles of participating companies at: https://b2idigital.com/5th-annual-roth-healthcare-opportunities-conference NeuroSense Therapeutics is a late-clinical stage biotechnology company developing novel treatments for severe neurodegenerative diseases, including amyotrophic lateral sclerosis (ALS) and Alzheimer's disease. The Company's lead product candidate, PrimeC, is a novel oral therapy designed to target multiple key biological pathways in ALS. NeuroSense has recently completed analysis of its Phase 2b PARADIGM study in ALS, supporting meaningful slowing of disease progression. The Company also reported significant biological activity across multiple biomarkers associated with ALS, including microRNAs, supporting PrimeC's multi-target mechanism of action and representing a potentially important advance in the treatment of ALS. NeuroSense has received clearance from the U.S. Food and Drug Administration (FDA) to initiate a pivotal Phase 3 clinical trial (PARAGON) in ALS, which is expected to enroll approximately 300 participants, primarily in the United States. Credit to the team at ROTH: Byron Roth, Aaron Gurewitz, Isabel Mattson-Pain, Nazan Akdeniz, Otilia "Charo" Montano, Amanda McAdams, Russ Nudelman, Andrew Kellogg, Matthew Robinson, David Farina, Jonathan Aschoff, Ph.D. and Harry Fong. ROTH built the day around time with management, in a 25-minute 1-on-1 and small group format running from 8:00 AM to 4:30 PM that gives institutional investors extended interaction with the executives running these companies, alongside a keynote. This is an invitation-only event and registration is subject to approval by ROTH. To request registration: https://www.meetmax.com/sched/event_139361/conference_home.html Participating company website: http://www.neurosense-tx.com/ Conference features include: • 1-on-1 and small group meetings between executive management and institutional investors, running from 8:00 AM to 4:30 PM • A 25-minute format built for extended interaction with the executives running these companies • Themed panel discussions across biotech, life science tools and diagnostics, and medtech, together with a keynote B2i Digital, The Capital Markets Matchmaker℠, carries each participating company's story From Marketing to Meetings℠, across its media network with a combined monthly audience of more than 330 million and its own community of 1.7 million+ investors and market participants. ROTH is a relationship-driven investment bank focused on serving growth companies and their investors across capital raising, equity research, sales and trading, mergers and acquisitions (M&A) advisory, and corporate access. For more information, visit www.roth.com. Discover more Featured Companies, Featured Experts, and upcoming Featured Conferences at b2idigital.com. B2i Digital is not a broker-dealer or investment adviser. This post is informational and not an offer or solicitation regarding any security. See the complete Disclosure at https://b2idigital.com/disclaimer. #Investing #StockToks #Stock
0.0% ERengagement of this clip — above the author's average (0.00%)
top 100%outperforms 0% of the author's clips
90%of the author's average views
